News & Research - HBM Partners AG

NEWS & RESEARCH

Portfolio News

HBM in the News

HBM M&A Report

ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing (28 KB)
27.3.2023
Download
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering (33 KB)
9.2.2023
Download
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson’s Disease (170 KB)
7.2.2023
Download
SWIXX and BioCryst partner for ORLADEYO® (berotralstat) in Central and Eastern Europe (160 KB)
24.1.2023
Download
SWIXX and Jazz Pharmaceuticals expand partnership with agreement to now distribute EPIDYOLEX® (CANNABIDIOL) in CEE territory (201 KB)
20.1.2023
Download
Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India (153 KB)
10.1.2023
Download
SWIXX and Kyowa Kirin expand Partnership for Rare Disease Portfolio to 13 Countries in Europe (172 KB)
19.12.2022
Download
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension (121 KB)
16.11.2022
Download
Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid) (407 KB)
15.11.2022
Download
Swixx and Kyowa Kirin enter into Partnership for Rare Disease Medicines Portfolio in Poland (165 KB)
10.10.2022
Download

<1 234 5 6 >

„Ungebremste Innovationskraft" (628 KB)
1.5.2019
Download Read more
Unbridled Capacity for Innovation (101 KB)
1.5.2019
Download Read more
Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)
23.1.2019
Download Read more
Investing in listed private equity – more than just an alternative (197 KB)
23.1.2019
Download Read more
Kleine Hersteller, grosses Potenzial (1007 KB)
1.1.2019
Download Read more
Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)
4.11.2018
Download Read more
A Biotechnology Bonanza (397 KB)
1.10.2018
Download Read more
Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)
13.8.18
Download Read more
Die Reize der Swiss Biotechs (581 KB)
25.7.2018
Download Read more
Der Kampf gegen das Vergessen (561 KB)
4.6.2018
Download Read more
Die Zuversicht für den Biotech-Sektor wächst (328 KB)
18.11.2017
Download Read more
Novartis setzt auf Nuklearmedizin (106 KB)
31.10.2017
Download Read more
Novartis's neue Wette im Krebsgeschäft (1502 KB)
31.10.2017
Download Read more
Trends und Chancen für den Anleger (840 KB)
1.9.2017
Download Read more
Strong Vital Signs in Biotech Innovation (4732 KB)
1.9.2017
Download Read more
Fokus auf Innovation (118 KB)
1.9.2017
Download Read more
Wie Anleger erfolgreich in Biotech investieren (535 KB)
27.5.2017
Download Read more
Trump und Big Pharma sind eine Hassliebe (166 KB)
4.2.2017
Download Read more
Fondsspezialitäten und ihre Macher (138 KB)
1.2.2017
Download Read more
Wie Biotech-Aktien auf Donald Trump reagieren (683 KB)
26.1.2017
Download Read more

<1 234 >

HBM Biopharma M&A Report 2022

HBM Biopharma M&A Database 2005-2022 (Excel)

Credits

Sitemap

ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing (28 KB)

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering (33 KB)

Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson’s Disease (170 KB)

SWIXX and BioCryst partner for ORLADEYO® (berotralstat) in Central and Eastern Europe (160 KB)

SWIXX and Jazz Pharmaceuticals expand partnership with agreement to now distribute EPIDYOLEX® (CANNABIDIOL) in CEE territory (201 KB)

Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India (153 KB)

SWIXX and Kyowa Kirin expand Partnership for Rare Disease Portfolio to 13 Countries in Europe (172 KB)

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension (121 KB)

Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid) (407 KB)

Swixx and Kyowa Kirin enter into Partnership for Rare Disease Medicines Portfolio in Poland (165 KB)

„Ungebremste Innovationskraft" (628 KB)

Unbridled Capacity for Innovation (101 KB)

Investieren in Listed Private Equity - mehr als eine Alternative (2023 KB)

Investing in listed private equity – more than just an alternative (197 KB)

Kleine Hersteller, grosses Potenzial (1007 KB)

Investieren in den Gesundheitssektor – Chancen für den Anleger (487 KB)

A Biotechnology Bonanza (397 KB)

Andreas Wicki, CEO HBM Healthcare Investments, im Interview (345 KB)

Die Reize der Swiss Biotechs (581 KB)

Der Kampf gegen das Vergessen (561 KB)

Die Zuversicht für den Biotech-Sektor wächst (328 KB)

Novartis setzt auf Nuklearmedizin (106 KB)

Novartis's neue Wette im Krebsgeschäft (1502 KB)

Trends und Chancen für den Anleger (840 KB)

Strong Vital Signs in Biotech Innovation (4732 KB)

Fokus auf Innovation (118 KB)

Wie Anleger erfolgreich in Biotech investieren (535 KB)

Trump und Big Pharma sind eine Hassliebe (166 KB)

Fondsspezialitäten und ihre Macher (138 KB)

Wie Biotech-Aktien auf Donald Trump reagieren (683 KB)